WHWK PE Ratio & Valuation,Is WHWK Overvalued

WHWK Relative Valuation

WHWK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WHWK is overvalued; if below, it's undervalued.

Historical Valuation

Whitehawk Therapeutics Inc (WHWK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.45 is considered Undervalued compared with the five-year average of -2.47. The fair price of Whitehawk Therapeutics Inc (WHWK) is between 3.47 to 4.68 according to relative valuation methord. Compared to the current price of 2.70 USD , Whitehawk Therapeutics Inc is Undervalued By 22.29%.

Relative Value

Fair Zone

3.47-4.68

Current Price：2.70

22.29%

Undervalued

-3.96

0.00

EV/EBITDA

Whitehawk Therapeutics Inc. (WHWK) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.81

EV/EBIT

Whitehawk Therapeutics Inc. (WHWK) has a current EV/EBIT of 0.81. The 5-year average EV/EBIT is 1.25. The thresholds are as follows: Strongly Undervalued below -1.80, Undervalued between -1.80 and -0.28, Fairly Valued between 2.77 and -0.28, Overvalued between 2.77 and 4.29, and Strongly Overvalued above 4.29. The current Forward EV/EBIT of 0.81 falls within the Historic Trend Line -Fairly Valued range.

3.45

Whitehawk Therapeutics Inc. (WHWK) has a current PS of 3.45. The 5-year average PS is 2.49. The thresholds are as follows: Strongly Undervalued below 0.57, Undervalued between 0.57 and 1.53, Fairly Valued between 3.45 and 1.53, Overvalued between 3.45 and 4.41, and Strongly Overvalued above 4.41. The current Forward PS of 3.45 falls within the Overvalued range.

0.00

P/OCF

Whitehawk Therapeutics Inc. (WHWK) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.35. The thresholds are as follows: Strongly Undervalued below -2.01, Undervalued between -2.01 and -1.18, Fairly Valued between 0.48 and -1.18, Overvalued between 0.48 and 1.31, and Strongly Overvalued above 1.31. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.53

P/FCF

Whitehawk Therapeutics Inc. (WHWK) has a current P/FCF of -1.53. The 5-year average P/FCF is -5.77. The thresholds are as follows: Strongly Undervalued below -20.95, Undervalued between -20.95 and -13.36, Fairly Valued between 1.82 and -13.36, Overvalued between 1.82 and 9.42, and Strongly Overvalued above 9.42. The current Forward P/FCF of -1.53 falls within the Historic Trend Line -Fairly Valued range.

Whitehawk Therapeutics Inc (WHWK) has a current Price-to-Book (P/B) ratio of 0.73. Compared to its 3-year average P/B ratio of 0.59 , the current P/B ratio is approximately 23.65% higher. Relative to its 5-year average P/B ratio of 0.59, the current P/B ratio is about 23.65% higher. Whitehawk Therapeutics Inc (WHWK) has a Forward Free Cash Flow (FCF) yield of approximately -83.47%. Compared to its 3-year average FCF yield of -85.68%, the current FCF yield is approximately -2.57% lower. Relative to its 5-year average FCF yield of -85.68% , the current FCF yield is about -2.57% lower.

0.73

P/B

Median3y

0.59

Median5y

0.59

-83.47

FCF Yield

Median3y

-85.68

Median5y

-85.68

Competitors Valuation Multiple

The average P/S ratio for WHWK's competitors is 13.97, providing a benchmark for relative valuation. Whitehawk Therapeutics Inc Corp (WHWK) exhibits a P/S ratio of 3.45, which is -75.31% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of WHWK decreased by 7.29% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.51 to -7.87.

The secondary factor is the Revenue Growth, contributed -100.00%to the performance.

Overall, the performance of WHWK in the past 1 year is driven by P/E Change. Which is more unsustainable.

-100.00%

7.21M → 0.00

Revenue Growth

-121.36%

-173.96 → 37.16

Margin Expansion

214.07%

-2.51 → -7.87

P/E Change

-7.29%

2.88 → 2.67

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Whitehawk Therapeutics Inc (WHWK) currently overvalued or undervalued?

What is Whitehawk Therapeutics Inc (WHWK) fair value?

WHWK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Whitehawk Therapeutics Inc (WHWK) is between 3.47 to 4.68 according to relative valuation methord.

How does WHWK's valuation metrics compare to the industry average?

What is the current P/B ratio for Whitehawk Therapeutics Inc (WHWK) as of Jan 09 2026?

As of Jan 09 2026, Whitehawk Therapeutics Inc (WHWK) has a P/B ratio of 0.73. This indicates that the market values WHWK at 0.73 times its book value.

What is the current FCF Yield for Whitehawk Therapeutics Inc (WHWK) as of Jan 09 2026?

As of Jan 09 2026, Whitehawk Therapeutics Inc (WHWK) has a FCF Yield of -83.47%. This means that for every dollar of Whitehawk Therapeutics Inc’s market capitalization, the company generates -83.47 cents in free cash flow.

What is the current Forward P/E ratio for Whitehawk Therapeutics Inc (WHWK) as of Jan 09 2026?

As of Jan 09 2026, Whitehawk Therapeutics Inc (WHWK) has a Forward P/E ratio of -3.96. This means the market is willing to pay $-3.96 for every dollar of Whitehawk Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Whitehawk Therapeutics Inc (WHWK) as of Jan 09 2026?

As of Jan 09 2026, Whitehawk Therapeutics Inc (WHWK) has a Forward P/S ratio of 3.45. This means the market is valuing WHWK at $3.45 for every dollar of expected revenue over the next 12 months.

WHWK Valuation